PL3065828T3 - Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych - Google Patents

Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych

Info

Publication number
PL3065828T3
PL3065828T3 PL14860231T PL14860231T PL3065828T3 PL 3065828 T3 PL3065828 T3 PL 3065828T3 PL 14860231 T PL14860231 T PL 14860231T PL 14860231 T PL14860231 T PL 14860231T PL 3065828 T3 PL3065828 T3 PL 3065828T3
Authority
PL
Poland
Prior art keywords
materials
methods
hematological malignancies
treating hematological
treating
Prior art date
Application number
PL14860231T
Other languages
English (en)
Inventor
Ayalew Tefferi
Original Assignee
Mayo Foundation For Medical Education And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation For Medical Education And Research filed Critical Mayo Foundation For Medical Education And Research
Publication of PL3065828T3 publication Critical patent/PL3065828T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL14860231T 2013-11-06 2014-11-05 Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych PL3065828T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361900854P 2013-11-06 2013-11-06
US201361904195P 2013-11-14 2013-11-14
PCT/US2014/064112 WO2015069758A1 (en) 2013-11-06 2014-11-05 Methods and materials for treating hematological malignancies
EP14860231.1A EP3065828B1 (en) 2013-11-06 2014-11-05 Methods and materials for treating hematological malignancies

Publications (1)

Publication Number Publication Date
PL3065828T3 true PL3065828T3 (pl) 2019-06-28

Family

ID=53042029

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14860231T PL3065828T3 (pl) 2013-11-06 2014-11-05 Sposoby i materiały do leczenia złośliwych nowotworów hematologicznych

Country Status (17)

Country Link
US (1) US11123359B2 (pl)
EP (2) EP3065828B1 (pl)
JP (1) JP6532478B2 (pl)
AU (1) AU2014346840B2 (pl)
CA (1) CA2929809C (pl)
CY (1) CY1122229T1 (pl)
DK (1) DK3065828T3 (pl)
ES (1) ES2717777T3 (pl)
HR (1) HRP20190538T1 (pl)
HU (1) HUE042792T2 (pl)
LT (1) LT3065828T (pl)
PL (1) PL3065828T3 (pl)
PT (1) PT3065828T (pl)
RS (1) RS58659B1 (pl)
SI (1) SI3065828T1 (pl)
SM (1) SMT201900185T1 (pl)
WO (1) WO2015069758A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
EP3658156B1 (en) * 2017-07-28 2026-03-25 Geron Corporation Telomerase inhibitor for use in treating a myelodysplastic syndrome
CN112770783B (zh) * 2018-07-31 2025-02-25 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
CN113631719A (zh) 2018-11-29 2021-11-09 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法
CA3181682A1 (en) * 2020-07-17 2022-01-20 Anil Kapur Subcutaneous telomerase inhibitor compositions and methods for using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4600359A2 (en) * 2006-10-30 2025-08-13 Geron Corporation Combined telomerase inhibitor and gemcitabine for the treatment of cancer
ES2616055T3 (es) 2010-02-12 2017-06-09 Qiagen Marseille ASXL1 como nuevo marcador de diagnóstico de neoplasias mieloides
US20140303191A1 (en) 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US9186295B2 (en) * 2011-10-25 2015-11-17 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US20130316014A1 (en) * 2012-04-02 2013-11-28 Jaroslaw P. Maciejewski Methods for predicting prognosis of a subject with a myeloid malignancy
US9375485B2 (en) * 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
PT3456333T (pt) * 2012-12-07 2020-06-01 Geron Corp Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
CN112770783B (zh) 2018-07-31 2025-02-25 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法

Also Published As

Publication number Publication date
DK3065828T3 (en) 2019-04-15
SMT201900185T1 (it) 2019-05-10
RS58659B1 (sr) 2019-05-31
HRP20190538T1 (hr) 2019-05-17
EP3539547A1 (en) 2019-09-18
SI3065828T1 (sl) 2019-04-30
JP6532478B2 (ja) 2019-06-19
EP3065828B1 (en) 2019-01-09
LT3065828T (lt) 2019-04-10
US20160287625A1 (en) 2016-10-06
WO2015069758A1 (en) 2015-05-14
EP3065828A1 (en) 2016-09-14
HUE042792T2 (hu) 2019-07-29
US11123359B2 (en) 2021-09-21
ES2717777T3 (es) 2019-06-25
JP2016537423A (ja) 2016-12-01
CY1122229T1 (el) 2020-11-25
AU2014346840B2 (en) 2020-02-06
CA2929809A1 (en) 2015-05-14
CA2929809C (en) 2022-05-17
EP3065828A4 (en) 2017-07-19
AU2014346840A1 (en) 2016-06-02
PT3065828T (pt) 2019-04-01

Similar Documents

Publication Publication Date Title
IL281058A (en) Compositions and methods for treating anemia
IL245778B (en) Methods and preparations for the treatment of hemophilia
IL245281A0 (en) Methods and preparations for the treatment of cancer
SMT202200002T1 (it) Anticorpi anti-lag-3 per trattare tumori ematologici maligni
GB201420103D0 (en) Treating particles
IL244118A0 (en) Compounds and methods for the treatment of chronic urticaria
GB201312318D0 (en) Novel methods and compounds
GB201305414D0 (en) Method and composition
IL244353A0 (en) Compounds and use for cancer treatment
PL2967127T3 (pl) Sposoby redukcji jednej lub więcej nitrozoamn właściwych dla tytoniu w materiale tytoniowym
SMT201900185T1 (it) Metodi e materiali per trattare neoplasie maligne ematologiche
PL2964334T3 (pl) Kompozycje i sposoby do zabiegów dla uszkodzonych włosów
EP3065755A4 (en) Methods for treating hematological malignancies
GB2515316B (en) Methods for composite material processing
GB201411429D0 (en) Methods for monitoring treatment response and relapse in ovarian cancer
IL246069A0 (en) Preparations and methods for the treatment of malignant blood diseases
IL246185A0 (en) Methods and compositions for treating dysregulation in systems
GB2519829B (en) Methods for monitoring treatment response and relapse in breast cancer
GB201314922D0 (en) Materials and methods for treating ARID1A deficent Cancer
ZA201408732B (en) Composition and methods for treating wounds
GB201319951D0 (en) Treating Particle